Mycosis fungoides is the most common T-cell lymphoma of the skin from peripheral mature cells. It has an indolent course, progressing over several years or even decades. Treatment choice depends on the clinical form, stage, and the presence of generalization signs. Current therapeutic options for the classical mycosis fungoides at different stages of the disease are considered. In the early disease stages of IA, IB, and IIA (according to ISLE-EORTC guidelines), treatment may be limited to topical methods, including glucocorticosteroids, narrow-band mid-wave UV therapy, and photochemotherapy with psoralen. Cytostatics and genetically engineered biologics are used in the later stages of the disease. Phototherapy, PUVA, and radiation therapy are used in some other countries. For the systemic therapy of mycosis fungoides, along with monoclonal antibodies (brentuximab vedotin, mogamulizumab, alemtuzumab), histone deacetylase inhibitors (vorinostat, romidepsin) and cytokines (IFN-α, IFN-γ, IL-12) retinoids are used. Prospects for the duvelisib use, requiring further research, have also been considered. Systemic therapy includes chemotherapy (both monotherapy and combinations) and extracorporeal photopheresis (more suitable for patients with blood involvement at B1 or B2 stages). However, allogeneic hematopoietic stem cell transplantation is the only cure.